A uniform regimen enables decentralized care of diabetic pregnancies.
OBJECTIVE
A nationwide recommendation to standardize the care of diabetic pregnancies in different hospitals was given in Finland in 1993. The Medical Birth Register (MBR) was used to investigate whether these recommendations have been accepted and how they have affected the outcome of newborns.


METHODS
Data on 1442 singleton pregnancies complicated by insulin-treated diabetes in 1991-1995 were obtained from the MBR.


RESULTS
The incidence of insulin treatment during pregnancy was 4.5 per 1000 births. Sixty-six per cent (n = 954) of all women had Type 1 diabetes. During the study period, the number of deliveries managed in tertiary centres decreased from 59% to 47% (95% confidence interval [CI] 39-58%) and care was more often carried out on an out-patient basis. The perinatal mortality rate (>or= 28 weeks of gestation) declined from 19.3 to 8.2/1000, being 12.6/1000 in the whole diabetic population and 5.5/1000 in the general population (95% CI 3.4-8.8/1000). The risk was especially increased in insulin-treated gestational diabetic (GDM) pregnancies (14.3/1000). The proportion of macrosomic newborns (31.7%) in diabetic women was significantly higher than among the general population (3.2%) (95% CI 27.0-33.9%).


CONCLUSIONS
The decentralization and change-over to a mainly out-patient basis of management does not appear to have increased the number of cases of adverse outcome of diabetic pregnancy when patients have been selected to the appropriate level of care. The risks in insulin-treated GDM pregnancies were almost similar to Type 1 diabetes. To succeed, there must be a standardized care programme, continuous education and motivated personnel.
Vääräsmäki
M
M
Department of Obstetrics and Gynaecology, University of Oulu, Finland. marja.vaarasmaki@oulu.fi
Gissler
M
M
Hartikainen
A L
AL
D001724:Birth Weight; D002585:Cesarean Section; D003922:Diabetes Mellitus, Type 1 / Q000628:therapy*; D016640:Diabetes, Gestational / Q000188:drug therapy; D005260:Female; D005387:Finland; D006801:Humans; D007226:Infant Mortality; D007231:Infant, Newborn; D007328:Insulin / Q000627:therapeutic use; D007752:Obstetric Labor, Premature / Q000453:epidemiology; D011247:Pregnancy; D011256:Pregnancy Outcome; D011254:Pregnancy in Diabetics / Q000628:therapy*; D013812:Therapeutics / Q000592:standards*
D007328:Insulin